Recombinant humanized (from mouse) antibody expressed in CHO binding to human Complement component 5. Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.
Figure 1 Pharmacodynamics of Pexelizumab.
Mean hemolytic activity plus or minus standard error versus time of greater than 96 hours after placebo or pexelizumab bolus for all three treatment groups.
Shernan, S. K., Fitch, J. C., Nussmeier, N. A., Chen, J. C., Rollins, S. A., Mojcik, C. F., ... & Gangahar, D. M. (2004). Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. The Annals of thoracic surgery, 77(3), 942-949.
Figure 2 Post hoc assessment of pexelizumab efficacy in isolated coronary artery bypass graft patients across all treatment groups.
Data are presented as the incidence of the composite of death or myocardial infarction (any postoperative myocardial-specific isoform of creatine kinase [CK-MB] 100 ng/mL) and its individual components through postoperative day 30. Compared with the placebo group< the pexelizumab bolus plus infusion group reduced myocardial infarction by 66%. Death rates for the pexelizumab bolus plus infusion and placebo populations were 0.4% versus 1.9%, respectively. Error bars represent the standard error of the occurrence rate.
Shernan, S. K., Fitch, J. C., Nussmeier, N. A., Chen, J. C., Rollins, S. A., Mojcik, C. F., ... & Gangahar, D. M. (2004). Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. The Annals of thoracic surgery, 77(3), 942-949.
Figure 3 Histogram of number of enrolled patients in Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery (PRIMO-CABG) I (gray line) compared with PRIMO-CABG II (black line).
Calculated average intended enrollment threshold for PRIMO-CABG II (vertical line) placed at 2% predicted mortality.
Smith, P. K., Shernan, S. K., Chen, J. C., Carrier, M., Verrier, E. D., Adams, P. X., ... & PRIMO-CABG II Investigators. (2011). Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. The Journal of thoracic and cardiovascular surgery, 142(1), 89-98.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1370CL-S(P) | Mouse Anti-C5 Recombinant Antibody; scFv Fragment (TAB-1370CL-S(P)) | ELISA | Mouse scFv |
TAB-1371CL-S(P) | Mouse Anti-C5 Recombinant Antibody; scFv Fragment (TAB-1371CL-S(P)) | Inhib, FuncS | Mouse scFv |
TAB-1382CL-S(P) | Mouse Anti-C5 Recombinant Antibody; scFv Fragment (TAB-1382CL-S(P)) | ELISA, Inhib | Mouse scFv |
TAB-1383CL-S(P) | Mouse Anti-C5 Recombinant Antibody; scFv Fragment (TAB-1383CL-S(P)) | ELISA, Inhib | Mouse scFv |
TAB-1383CL-F(E) | Mouse Anti-C5 Recombinant Antibody; Fab Fragment (TAB-1383CL-F(E)) | ELISA, Inhib | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1372CL-F(E) | Human Anti-C5 Recombinant Antibody; Fab Fragment (TAB-1372CL-F(E)) | Inhib, FuncS | Humanized Fab |
TAB-1373CL-F(E) | Human Anti-C5 Recombinant Antibody; Fab Fragment (TAB-1373CL-F(E)) | IB, Inhib | Humanized Fab |
TAB-1374CL-F(E) | Human Anti-C5 Recombinant Antibody; Fab Fragment (TAB-1374CL-F(E)) | ELISA, Inhib | Humanized Fab |
TAB-1375CL-F(E) | Human Anti-C5 Recombinant Antibody; Fab Fragment (TAB-1375CL-F(E)) | ELISA, Inhib | Humanized Fab |
TAB-1376CL-F(E) | Human Anti-C5 Recombinant Antibody; Fab Fragment (TAB-1376CL-F(E)) | ELISA, Inhib | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-082CQ | Mouse Anti-C5 Recombinant Antibody (clone CBL249) | ELISA, Neut | Mouse IgG2a |
NEUT-083CQ | Mouse Anti-C5 Recombinant Antibody (clone MM0608-6H13) | ELISA, Neut, WB | Mouse IgG1 |
NEUT-084CQ | Mouse Anti-C5 Recombinant Antibody (clone CBL030) | ELISA, WB, Neut | Mouse IgG1 |
NEUT-085CQ | Mouse Anti-C5 Recombinant Antibody (clone CBL250) | ELISA, WB, IHC, FuncS | Mouse IgG1 |
NEUT-086CQ | Mouse Anti-C5 Recombinant Antibody (clone G25/2) | ELISA, IP, WB, Neut | Mouse IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-088CQ | Mouse Anti-C5 Recombinant Antibody (clone CBL771) | WB, Block, ELISA | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-4104 | Hi-Affi™ Rabbit Anti-C5 Recombinant Antibody (clone SI175DS) | IHC-P | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-453CQ | Anti-Human C5 Recombinant Antibody (Tesidolumab) | ELISA, IHC, FC, IP, IF, FuncS | IgG1, λ2 |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0609-CN | Human Anti-C5 Recombinant Antibody (HPAB-0609-CN) | ELISA, Block | Humanized IgG |
HPAB-0611-CN | Rabbit Anti-C5 Recombinant Antibody (HPAB-0611-CN) | PK, SPR, IF, ELISA, WB, FC | Rabbit IgG |
HPAB-0612-CN | Human Anti-C5 Recombinant Antibody (HPAB-0612-CN) | PK, WB, ELISA, FC | Humanized IgG |
HPAB-0613-CN | Human Anti-C5 Recombinant Antibody (HPAB-0613-CN) | WB, ELISA, FC | Humanized IgG |
HPAB-0614-CN | Mouse Anti-C5 Recombinant Antibody (clone m5G1.1) | Inhib, FuncS, WB, ELISA, IF, IP, Block | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0609-CN-F(E) | Human Anti-C5 Recombinant Antibody; Fab Fragment (HPAB-0609-CN-F(E)) | ELISA, Block | Humanized Fab |
HPAB-0611-CN-F(E) | Rabbit Anti-C5 Recombinant Antibody; Fab Fragment (HPAB-0611-CN-F(E)) | WB, ELISA, FC | Rabbit Fab |
HPAB-0612-CN-F(E) | Human Anti-C5 Recombinant Antibody; Fab Fragment (HPAB-0612-CN-F(E)) | WB, ELISA, FC | Humanized Fab |
HPAB-0652LY-F(E) | Mouse Anti-C5 Recombinant Antibody; Fab Fragment (HPAB-0652LY-F(E)) | IP, RIA, ELISA, WB | Mouse Fab |
HPAB-0653LY-F(E) | Mouse Anti-C5 Recombinant Antibody; Fab Fragment (HPAB-0653LY-F(E)) | IP, RIA, ELISA, WB | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0123-LS-S(P) | Mouse Anti-C5 Recombinant Antibody; scFv Fragment (HPAB-0123-LS-S(P)) | Block, ELISA | Mouse scFv |
HPAB-1794LY-S(P) | Human Anti-C5 Recombinant Antibody; scFv Fragment (HPAB-1794LY-S(P)) | ELISA, Block | Human scFv |
HPAB-1795LY-S(P) | Human Anti-C5 Recombinant Antibody; scFv Fragment (HPAB-1795LY-S(P)) | ELISA, Block | Human scFv |
HPAB-1796LY-S(P) | Human Anti-C5 Recombinant Antibody; scFv Fragment (HPAB-1796LY-S(P)) | ELISA, Block | Human scFv |
HPAB-1577WJ-S(P) | Mouse Anti-C5 Recombinant Antibody; scFv Fragment (clone 5G1.1) | ELISA, WB | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
PABC-559 | Recombinant Llama Anti-C5 Single Domain Antibody (Nb36) | ELISA | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-453CQ | Afuco™ Anti-C5 ADCC Recombinant Antibody (Tesidolumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
AFC-TAB-008 | Afuco™ Anti-C5 ADCC Recombinant Antibody (Eculizumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-436CQ | Afuco™ Anti-C5 ADCC Recombinant Antibody (Olendalizumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-901. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.